Skip to main content
138 search results for:

PDE4 inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 06-10-2022 | Gout | News | Article
    News in brief

    SGLT2 inhibitors linked to lower gout risk than DPP-4 inhibitors

    SGLT2 inhibitors, a type of diabetes drug, are associated with a lower risk for gout than DPP-4 inhibitors, research suggests.

  2. 18-10-2022 | Psoriatic arthritis | News | Article

    Support for JAK inhibitors as ‘drug of choice’ for patients with PsA and significant joint disease

    JAK inhibitors show promise for the treatment of moderate-to-severe psoriasis and psoriatic arthritis, finds a systematic review and meta-analysis of more than 6000 patients.

  3. 08-07-2022 | Rheumatoid arthritis | News | Article

    TNF inhibitors linked to higher psoriasis risk than other RA treatments

    Treatment with TNF inhibitors is associated with a twofold increased risk for new-onset psoriasis compared with nonbiologic agents, suggest findings from a Danish cohort study.

  4. 04-06-2022 | EULAR 2022 | Conference coverage | Article

    Mixed results for MACE risk with JAK inhibitors in RA

    Two real-world studies looking at the risk for major cardiovascular events with JAK inhibitors versus TNF inhibitors in patients with rheumatoid arthritis show contradicting outcomes.

  5. 08-06-2022 | EULAR 2022 | Conference coverage | Article

    NSAID suppression of axSpA spinal progression greatest with COX-2 selective inhibitors

    Ten-year results from the GESPIC study support the use of NSAIDs for reducing radiographic spinal progression in patients with axial spondyloarthritis and suggest a stronger effect with cyclo-oxygenase-2 selective inhibitors than non-selective NSAIDs.

  6. 02-09-2021 | JAK inhibitors | News | Article
    Regulatory update

    FDA requires boxed warning updates for JAK inhibitors

    In addition, use of Janus kinase (JAK) inhibitors in the USA will be limited to certain patients with an inadequate response or intolerance to tumor necrosis factor (TNF) inhibitors.

  7. 31-03-2022 | Rheumatoid arthritis | News | Article

    Real-world study suggests similar effectiveness of tofacitinib, TNF inhibitors

    Findings from a rheumatoid arthritis registry study suggest that the JAK inhibitor tofacitinib may have comparable real-world effectiveness to TNF inhibitors.

  8. 14-03-2022 | Giant cell arteritis | News | Article

    Phase 2 trial supports further investigation of JAK inhibitors for giant cell arteritis

    Findings from a proof-of-concept trial provide preliminary evidence to suggest that the JAK inhibitor baricitinib is well tolerated and may have efficacy for the treatment of relapsing giant cell arteritis.

  9. 29-03-2022 | Ankylosing spondylitis | Adis Journal Club | Article
    BioDrugs

    Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry

    The efficacy and safety of TNF inhibitors was similar in patients with AS aged ≥ 50 and < 50 years.

  10. 09-02-2022 | Juvenile idiopathic arthritis | News | Article

    TNF inhibitors linked to psoriasis risk in children with JIA

    Exposure to tumor necrosis factor inhibitors is associated with a threefold increased risk for developing psoriasis in children with juvenile idiopathic arthritis, US study findings indicate.

  11. 14-01-2022 | Rheumatoid arthritis | News | Article

    JAK inhibitors may increase cholesterol in people with RA

    Treatment with any of the five JAK inhibitors approved for use in rheumatoid arthritis in the USA, Europe, or Japan may lead to an increase in serum cholesterol levels, suggest results of a systematic review and network meta-analysis.

  12. 08-02-2022 | Rheumatoid arthritis | News | Article
    News in brief

    Disease activity may be a risk factor for herpes zoster in RA patients taking JAK inhibitors

    Having several changes in targeted therapy and high disease activity are associated with an elevated risk for herpes zoster among people with rheumatoid arthritis receiving treatment with JAK inhibitors, indicate study findings published in RMD Open .

  13. 21-10-2021 | Infection | News | Article

    TNF inhibitors linked to more serious infections in RA vs PsA

    Individuals with rheumatoid arthritis have a significantly higher risk for serious infections while receiving TNF inhibitor therapy than those with psoriatic arthritis, Norwegian researchers report.

  14. 10-11-2021 | ACR 2021 | Conference coverage | Article

    ORAL Surveillance: Tofacitinib fails to show noninferiority vs TNF inhibitors for MACE, malignancy risk

    The JAK inhibitor tofacitinib is associated with numerically higher rates of MACE and malignancy than TNF inhibitors in people with rheumatoid arthritis at high cardiovascular risk, show the ORAL Surveillance results.

  15. 23-11-2021 | Adult-onset Still's disease | News | Article

    Severe hypersensitivity to IL-1, IL-6 inhibitors linked to HLA-DRB1*15

    Human leucocyte antigen-DRB1*15 haplotypes are strongly associated with delayed drug reaction with eosinophilia and systemic symptoms in people receiving IL-1 or IL-6 inhibitors for Still’s disease, research suggests.

  16. 09-11-2021 | ACR 2021 | Conference coverage | Article

    Olokizumab benefits extend to patients with RA refractory to methotrexate or TNF inhibitors

    Olokizumab shows clinical and physical benefits for patients with rheumatoid arthritis with inadequate responses to methotrexate and TNF inhibitor therapy in the latest CREDO findings.

  17. 13-12-2021 | Mental health | Adis Journal Club | Article
    Rheumatology and Therapy

    Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    The pooled mean reduction in SF-36 MCS scores (after minus before) with JAK inhibitors was 4.95 (4.41–5.48).

  18. 13-10-2021 | COVID-19 | News | Article
    News in brief

    High overall response rates to COVID-19 vaccination in people taking JAK inhibitors

    Analysis of the MAJIK-SFR Registry suggests most people treated with JAK inhibitors mount an antibody response to COVID-19 vaccines.

  19. 28-09-2021 | Vaccination | News | Article

    Live attenuated zoster vaccine may be ‘reasonable option’ for people taking TNF inhibitors

    Findings from the VERVE trial suggest that the live attenuated zoster vaccine has favorable short-term immunogenicity and safety profiles in people with immune-mediated diseases treated with TNF inhibitors.

  20. 06-08-2021 | Rheumatoid arthritis | News | Article

    Study quantifies herpes zoster risk with JAK inhibitors, other DMARDs

    A comparison of different treatments for rheumatoid arthritis suggests that Janus kinase inhibitors are associated with the highest risk for herpes zoster, while some biologic DMARDs may also be linked to an increased risk.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.